Determining and comparing the effect of probiotic(Sabular) and Rosuvastatin on the success of four-drug treatment to eradicate Helicobacter pylori in patients referred to the Gastrointestinal Clinic of Al-Zahra Hospital from December 2023 to March 2025

Esfahan University of Medical Sciences0 个研究点目标入组 255 人开始时间: 待定最近更新: 2023年10月16日

试验速览

暂无简介。

•Having a positive stool antigen test for H. pylori
•Having at least one indication for the treatment of H. Pylori including: 1. Patients with dyspepsia and a positive stool Ag test for H. Pylori, (according to the prevalence >20% of Helicobacter pylori infection in the Iranian population) 2. Patients with resistant dyspepsia and Positive gastric biopsy for Helicobacter in endoscopy 3. Patients with dyspepsia with unknown cause and age less than 60 years who have a positive stool Ag test. 4. Patients with a positive stool Ag test who need long-term treatment with NSAID 5. Patients with early stages of gastric cancer who have undergone resection surgery. 6. Patients with a high risk of gastric cancer (first degree family of a person with gastric cancer, extensive gastritis or severe atrophy of gastric mucosa, history of gastric neoplasm) people treated with gastric acid secretion inhibitors for more than 1 year, the presence of environmental risk factors for stomach cancer or the patient's great fear of stomach cancer)

•Pregnancy and breastfeeding at the time of study
•Immune deficiency
•Recent history of macrolide use
•Allergy to penicillin
•Not currently taking statins and probiotics
•The presence of contraindications for rosuvastatin use (history of hypersensitivity reaction to rosuvastatin or substances added to the composition of rosuvastatin tablets, increased liver enzymes AST, ALT without a specific cause, acute liver failure, uncompensated liver cirrhosis, pregnancy or breastfeeding)

发起方